{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:07:53Z","timestamp":1767650873261,"version":"build-2065373602"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2512,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p>Citalopram, a selective serotonin reuptake inhibitor, is used in the management of anxiety disorders. A 55\u2010year\u2010old man receiving citalopram for panic disorder reported a decrease in the agent's therapeutic efficacy when rifampin was started for osteomyelitis. His condition improved when the rifampin was stopped. Rifampin is known to induce the metabolism of cytochrome P450 3A4 substrates and thus plays a role in several drug\u2010drug interactions. We suspect that the efficacy of citalopram was blunted with the concurrent use of rifampin. To our knowledge, only one other case of an interaction of rifampin with a selective serotonin reuptake inhibitor is described in the literature. Clinicians should monitor all drugs and dietary supplements that patients with psychiatric conditions take, regardless of the indication, intended purpose, or prescriber. This is especially important, however, for a drug that is pivotal to a patient's well\u2010being; its therapeutic effect should be carefully monitored when any new drug is added or a change in the dosage of a concurrent drug is made.<\/jats:p>","DOI":"10.1592\/phco.25.3.435.61591","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T05:32:07Z","timestamp":1112333527000},"page":"435-437","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Exacerbation of Panic Disorder with Rifampin Therapy in a Patient Receiving Citalopram"],"prefix":"10.1002","volume":"25","author":[{"given":"Oladipo","family":"Kukoyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami R.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Carnahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830160021003"},{"issue":"8","key":"e_1_2_1_3_2","first-page":"47","article-title":"Consensus statement on panic disorder from the international consensus group on depression and anxiety","volume":"59","author":"Ballenger JC","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03861.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198405000-00018"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.9.985"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00023"},{"volume-title":"Celexa (citalopram hydro\u2010bromide) package insert. St","year":"2002","author":"Forest Pharmaceuticals, Inc.","key":"e_1_2_1_8_2"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982597239921"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007451911843"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(82)80179-6"},{"issue":"2","key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0022-3565(24)36462-6","article-title":"Identification of cytochrome P450 isoforms in citalopram N\u2010demethylation by human liver microsomes","volume":"280","author":"Kobayashi K","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_13_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research.CDER new and generic drug approvals: 1998\u20132004 application 20822 clinical pharmacology and biopharmaceutics review. Available fromwww.fda.govcderapprovalindex.htm. Assessed October 1 2003."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4001"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3473"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.25.3.435.61591","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.25.3.435.61591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:41Z","timestamp":1761069581000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.25.3.435.61591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1592\/phco.25.3.435.61591"],"URL":"https:\/\/doi.org\/10.1592\/phco.25.3.435.61591","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}